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Abstract
Introduction: Cancer-associated retinopathy (CAR) is a paraneoplastic neurological syndrome resulting in progressive loss of
vision and clinical signs of retinal degeneration. It is associated with various types of cancer and is also considered to be an
autoimmune disorder that involves cross-reaction between autoantibodies and retinal proteins. The aim of this study was to
establish whether immunoreactivity to retinal antigens (RAs) observed in patients with breast cancer is accompanied by any
visual impairments. 
Materials and Methods: Sera of 295 patients with diagnosed breast cancer were screened for the presence of anti-RAs anti-
bodies using immunoblotting. Cellular immunoreactivity to RAs present in retinal extracts and to purified recoverin and
arrestin was determined by means of a lymphocyte proliferation assay. Six patients with high-titer antibodies to RAs then
underwent ophthalmic and neurological examinations. 
Results: Four serum samples contained high-titer antibodies to a 46-kDa protein, most probably retinal α-enolase, three had
antibodies to a 48-kDa protein identified as retinal arrestin, while 56-, 43-, 41-, and 34-kDa antigens were recognized only
by one serum sample each. Moreover, weak cellular response to all the RAs tested was observed in one patient and anoth-
er patient responded only to retinal extract. Two of the examined patients displayed symptoms of CAR.
Conclusions: Immunoreactivity to RAs in patients with breast cancer may also be present in cases without clinical signs of CAR. 
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blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate, toluidine salt, PNS – paraneoplastic neurological syn-
drome, RAs – retinal antigens, SCLC – small-cell lung cancer, SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel elec-
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INTRODUCTION
Cancer-associated retinopathy (CAR) is a paraneo-
plastic neurological syndrome (PNS) resulting in pro-
gressive loss of vision and clinical signs of retinal degen-
eration. It is associated with various types of cancer,
including small-cell lung cancer (SCLC), non-SCLC,
breast cancer, invasive thymoma, uterine cervical can-
cer, endometrial cancer, lymphoma, and others [15, 16,
25, 27]. The primary manifestation of CAR is rapid, pro-
gressive visual loss due to both rod and cone dysfunc-
tion. Clinical problems associated with cone dysfunction
include photosensitivity, decreased visual acuity, color
vision abnormalities as well as central scotomas, and an
abnormal cone-mediated electroretinogram (ERG).
Clinical problems associated with rod dysfunction
include nyctalopia, prolonged dark adaptation, periph-
eral or ring scotomas, and an abnormal rod-mediated
ERG [19, 28]. The results of ophthalmologic examina-
tion often show a triad of symptoms: photosensitivity,
ring scotomatous visual field loss, and attenuated retinal
arteriole caliber [12]. Fundus findings in patients are notspecific and could reveal normal fundus results, optic
disc pallor, narrowing of the retinal arterioles, and reti-
nal pigment epithelium changes [14, 17, 19, 28].
Similarly to other PNS, CAR is considered to be an
autoimmune disorder that involves cross-reaction
between autoantibodies and retinal proteins. Besides
antibodies, cytotoxic cells may also mediate paraneo-
plastic-associated symptoms. Sera of patients with CAR
have been shown to contain antibodies to several dis-
tinct retinal antigens (RAs), of which antibodies to a 23-
-kDa protein, identified as recoverin, appear to be the
most common [21], but antibodies to α-enolase [1, 3]
and 34-, 43-, 60-, 65-, and 70-kDa proteins have also
been detected [2, 9, 20, 24, 26]. Antibodies to some of
these RAs have also been found in other neurological
diseases [6]. On the other hand, it has also been report-
ed that the presence of antibodies against RAs is not
always accompanied by ocular symptoms [13, 23]. In this
context, the aim of our study was to evaluate whether
breast cancer patients whose sera or immunocompetent
cells recognize RAs display any visual impairments.
MATERIALS AND METHODS
Serum samples were obtained from 295 patients
diagnosed with breast cancer at the Institute of
Oncology, Gliwice, Poland. The selection time period
was six months. The mean interval time from the cancer
onset and the study examination was from 6–12 months
(mean 7.5 months). The sera were diluted 1:100 (stan-
dard dilution) and evaluated for the presence of anti-
bodies against soluble RAs using immunoblot analysis.
Six patients whose sera revealed high-titer antibodies to
RAs (sera reactive at a dilution of at least 1:200) under-
went ophthalmic and neurologic examinations. Their
response to RAs at the cellular level was also evaluated.
In all patients the presence of neoplasms of the central
nervous system and concurrent eye conditions affecting
the retina were excluded. They had no preceding illness
(cardiovascular, hematologic nor metabolic disorders),
trauma or toxin exposure. Non of them had a history of
drugs known to influence visual function (two of them
had received tamoxifen but after our examination). No
family history of retinal degeneration existed. All assays
and examinations were performed with the patients’
consent and in accordance with institutional review
board approval. 
A complete ophthalmological examination was per-
formed which included measurements of visual acuity,
electroretinography (ERG), visual evoked potentials
(VEP), intraocular pressure, indirect ophthalmoscopy
using a Volk lens, and visual field by static perimetry.
Best corrected visual acuity was measure using Snellen’s
scale. The ERG recordings (flash ERG and the 30 Hz
flicker ERG) were performed using Tomey P400 device.
Visual field was examined by means of an Octopus 101
perimeter. We performed the perimetric examination
twice, according to the ST program and TOP strategy.
VEPs were investigated with use of averaging system
manufactured by Nicolet (Nicolet CA-1000 averager). 
To examine the reactivity of the sera in immunoblot-
ting as well as the response at the cellular level, soluble
RAs present in retinal extract were used. Retinal extract
and purified RAs were obtained from dark-adapted
bovine retinas according to procedures described earli-
er [13]. Briefly, the retinas were homogenized under
dim red light in cold H2O containing 0.5 mM benzami-
dine and 20 µg/ml of leupeptin (Sigma, St. Louis, MO,
USA). The homogenate was centrifuged at 30,000×g 
for 30 min at 4°C and supernatant containing soluble pro-
teins (the retinal extract) was collected and further used as 
a source of RAs. Arrestin and recoverin were purified from
the retinal extracts by means of ion-exchange and Phenyl-
-Sepharose chromatographies, respectively. 
Immunoblotting analysis was performed as follows:
retinal extracts (10 µg of proteins) or purified RAs (1.0
µg) were resolved in SDS-PAGE using 12% acrylamide
gels and transferred onto nitrocellulose membranes
(Schleicher & Schuell, Dassel, Germany). The mem-
branes were blocked with 2% casein and incubated with
samples of analyzed sera diluted 1:100 and 1:200 and
then with anti-human IgG goat antibodies conjugated to
alkaline phosphatase (Promega, Madison, WI, USA).
Antibodies bound to RAs were visualized using
NBT/BCIP-based substrate (Promega, Madison, WI,
USA). The molecular masses of the detected proteins
were determined using a Vilber Lourmat GelDoc sys-
tem and BIO-CAPT and BIO-1D++ software.
The cellular immune response to RAs, either puri-
fied (recoverin and arrestin) or those present in the reti-
nal extract, was determined using a lymphocyte prolifer-
ation assay. Mononuclear cells were isolated from
heparinized peripheral blood by centrifugation in densi-
ty gradient using Histopaque 1077 (Sigma, St. Louis,
MO, USA) and cultured with or without RAs (10–40
µg/ml recoverin, arrestin, or retinal extract). Their pro-
liferative responses were determined by measuring the
incorporation of [3H]-thymidine (0.5 µCi; Amersham
Pharmacia Biotech, Uppsala, Sweden). The results are
expressed in the form of a stimulation index (SI), calcu-
lated as the ratio of mean counts per minute (cpm)
obtained from the cells stimulated with RAs and cpm
obtained from unstimulated control cells. In accordance
with reference [29], stimulation was considered positive
if SI was equal to or greater than 2.
RESULTS
The reactivity of the patients’ sera with RAs is pre-
sented in Fig. 1. Sera of four of the six patients (nos. 2,
3, 4, 6) contained high-titer antibodies (dilution above
1:200) to a 46-kDa protein, most probably retinal α-eno-
lase, three (nos. 1, 5, 6) had antibodies to a 48-kDa pro-
tein identified as retinal arrestin, while 56-, 43-, 41-, and
34-kDa antigens were recognized by one serum sample
each (nos. 4, 5, 3, and 1, respectively). 
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(no. 1) responded to retinal extract and to purified RAs
(mean SI≥2) and the lymphocytes of another (no. 3)
responded exclusively to retinal extract. The cells of the
remaining patients did not respond to any of the RAs
tested (Table 1). 
There were no neurological symptoms in three (nos.
1, 5, 6) of the six patients. In the other three (nos. 2, 3,
4) we found mild peripheral neuropathy (weak knee and
ankle reflex, peripheral hypoesthesia of the lower
extremities). The results of ophthalmological examina-
tion are shown in Table 2. All the patients had normal
intraocular pressure. Although all of them displayed
abnormal VEP, only two (nos. 1 and 2) showed abnor-
malities in ophthalmoscopy, visual field, and ERG. One
of these patients (no. 2) revealed high-titer serum anti-
bodies to the 46-kDa antigen, while the serum of the
other (no. 1) showed only moderate reactivity with RAs.
Interestingly, only this patient’s serum recognized a 34-
-kDa antigen. Cellular response to RAs was also most
significant in this patient’s lymphocytes (Table 1). 
DISCUSSION
CAR has been increasingly diagnosed during the 29
years since Sawyer’s discovery of it [22]. CAR always has
to be taken into the consideration when confronted with
a patient suffering from cancer and complaining of
“dimming” of vision with missing areas of visual field,
central and cecocentral scotomas, hemeralopia, photop-
sias, night blindness, loss of color vision, and photosen-
sitivity. Laboratory examination for CAR in such a case
is necessary. In our study group, a progressive decrease
in visual function appeared in two patients in the course
of six months and was bilateral. These signs and symp-
toms correlated with immunoreactivity to RAs, and the
presence of breast cancer supported the diagnosis of
CAR.
CAR symptoms may be observed before the diagno-
sis of cancer, as described in cases of SCLC, invasive
thymoma, and uterine cervical cancer [2, 8, 14], but it
has also been recognized after detecting a primary
malignancy. An example of CAR symptoms developing
after carcinoma was the case of a 65-year-old man who
underwent resection of adenocarcinoma of the lung. He
noticed a deterioration of vision 10 months later [19].
With regard to patients with breast cancer, two patients
have been reported who both presented paraneoplastic
retinopathy symptoms although their sera did not con-
tain antibodies to the most common RA in CAR, name-
ly recoverin [11]. In our patients the CAR symptoms
developed after the diagnosis of cancer and the lympho-
cytes of only one of them responded weakly to recov-
erin. However, their sera contained antibodies to the 46-
and 34-kDa proteins also detected in CAR patients with
SCLC [3] and endometrial carcinoma [24]. It has been
reported that breast cancer may also be associated with
cerebellar degeneration, sensoriomotor neuropathy,
and opsoclonus/myoclonus syndrome, which all repre-
sent PNSs other than CAR [5, 7]. In our three patients
we found mild peripheral neuropathy, which together
with other impairments (VEP pathology) may also indi-
cate a PNS. 
In conclusion, this study showed that antibodies to
RAs are present in the sera of patients with breast can-
cer. However, their presence correlated only in few
cases with the visual impairments characteristic for
CAR symptoms. Reactivity to RAs of sera in patients
with breast cancer could also be present in cases with-
out clinical signs of CAR. However, detecting and mon-
itoring the presence of anti-RAs antibodies as well as
their titers with parallel neurological and ophthalmic
examinations can be useful in patient management and
give an insight into the relations between a cancer and
the development of neurological and ophthalmic symp-
toms. 
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Table 1. Proliferation of blood mononuclear cells (BMCs) from
patients with breast cancer in response to retinal antigens
Patient no. Antigen
E Rcv Ar
1 2.22±0.21 2.09±0.37 2.02±0.58
2 −− −
3 2.16±0.12 −−
4 1.42±0.24 1.56±0.11 −
5 −− −
6 −− −
BMCs were stimulated with retinal extracts (E), recoverin (Rcv),
and arrestin (Ar) and then their proliferative responses were
determined as described in Materials and Methods. Results
obtained from at least three independent measurements are
expressed as a mean value of the stimulation index ±SE.
Fig. 1. Immunostaining of retinal antigens with sera of breast
cancer patients. Lanes labeled (E) or (A) contain retinal extract
or purified RAs (arrestin, recoverin, and guanylate cyclase-acti-
vating proteins), respectively. Antigens were immunostained
with patients’ sera diluted 1:200. Arrows indicate the positions
of molecular mass markers. 
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R – right eye, L – left eye, ms – milliseconds, µV – microvolt, VEP – visual evoked potentials; the latencies above 115.5 ms were
considered “abnormal”, following our previous studies in a normal population [4], ERG – electroretinogram; amplitudes and peak
times (30 Hz flicker ERG) below 115.20±60.74 µV and 20.14±4.12 ms were considered “reduced” following our previous studies
in a normal population (not reported) and other author’s studies [18]. 
Visual field was considered normal if extends to 35 degrees nasally, to 60 degrees temporally, 50 degrees above and below the hor-
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